DeutschNewstral
Article
bizjournals.com on 2015-02-24 21:10
Juno Therapeutics CEO gets $450,000 bonus, recruits former Amgen, Dendreon researchers
Related news
- Biotech investor explains why Juno Therapeutics won't be like Dendreonbizjournals.com
- Investors short Juno Therapeutics, Amgen stocks, but that may not be bad newsbizjournals.com
- Juno Therapeutics to open Bothell manufacturing facilitybizjournals.com
- Former Dendreon CEO, Amgen scientists team up on new immunotherapy startupbizjournals.com
Seattle’s Juno Therapeutics ready for another round in war on cancerseattletimes.com
Seattle’s Juno Therapeutics ready for another round in war on cancer - Mon, 25 Sep 2017 PSTThe Spokesman-Review
Juno Therapeutics gets $500K grant from state fundold.seattletimes.com- Amgen announces treatment to compete with Juno, other Seattle biotechs as it exits regionbizjournals.com
- Juno Therapeutics' Hans Bishop is one of the highest-paid CEOs in the U.S.bizjournals.com
- Juno Therapeutics shuts down clinical trial of one of its cancer drugsseattletimes.com
- Juno Therapeutics will have some competition in the race to use immunotherapy to cure cancerbizjournals.com
- Juno Therapeutics scoops up 3 floors in new Alexandria building in South Lake Unionbizjournals.com
- Celgene completes acquisition of Juno Therapeuticsseattletimes.com
Juno Therapeutics ends cancer drug trialKING 5- Juno Therapeutics plans Bothell manufacturing plantseattletimes.com
- Juno makes key hire from Amgen to bolster commercialization effortsbizjournals.com
- Juno Therapeutics: Will cash burn hurt outlook after Monday's earnings?bizjournals.com
- Juno Therapeutics suspends drug trial after new patient deathsseattletimes.com
- Juno Therapeutics shopping for new headquarters in Seattlebizjournals.com
Amgen to buy Horizon Therapeutics in $26.4-billion dealLA Times